COPENHAGEN, Denmark, November 7, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% of the shares and voting rights in Bavarian Nordic A/S as of October 31, 2025.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.
Contact investors:
Europe: Disa Tuominen, IR Manager, [email protected]
US: Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03
Company Announcement no. 41 / 2025
Attachment
Company Announcement no. 41 / 2025
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Published 1 day ago
Nov 7, 2025 at 4:30 PM
Neutral
